141 related articles for article (PubMed ID: 32239370)
1. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Hou J; Cao X; Cheng Y; Wang X
Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
[TBL] [Abstract][Full Text] [Related]
2. MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
Togashi Y; Mizuuchi H; Tomida S; Terashima M; Hayashi H; Nishio K; Mitsudomi T
Lung Cancer; 2015 Dec; 90(3):590-7. PubMed ID: 26547802
[TBL] [Abstract][Full Text] [Related]
3. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Park MY; Jung MH; Eo EY; Kim S; Lee SH; Lee YJ; Park JS; Cho YJ; Chung JH; Kim CH; Yoon HI; Lee JH; Lee CT
Oncotarget; 2017 May; 8(22):36331-36338. PubMed ID: 28422737
[TBL] [Abstract][Full Text] [Related]
4. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
Tsukumo Y; Naito M; Suzuki T
PLoS One; 2020; 15(3):e0229712. PubMed ID: 32130260
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
6. Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.
Nguyen T; Aida T; Iijima-Yamashita Y; Tamai M; Nagamachi A; Kagami K; Komatsu C; Kasai S; Akahane K; Goi K; Inaba T; Sanada M; Inukai T
Cancer Sci; 2024 Jun; 115(6):1924-1935. PubMed ID: 38549229
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
8. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
9. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
10. Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma.
Mao Y; Xu R
Biomed Pharmacother; 2020 Mar; 123():109771. PubMed ID: 31881486
[TBL] [Abstract][Full Text] [Related]
11. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Editing of the
Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
[TBL] [Abstract][Full Text] [Related]
13.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions.
Su D; Feng X; Colic M; Wang Y; Zhang C; Wang C; Tang M; Hart T; Chen J
DNA Repair (Amst); 2020 Mar; 87():102803. PubMed ID: 31991288
[TBL] [Abstract][Full Text] [Related]
15. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Directed Gene Editing as a Method to Reduce Chemoresistance in Lung Cancer Cells.
Rivera-Torres N; Bialk P; Kmiec EB
Methods Mol Biol; 2023; 2660():263-271. PubMed ID: 37191803
[TBL] [Abstract][Full Text] [Related]
17. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice.
Rogers ZN; McFarland CD; Winters IP; Seoane JA; Brady JJ; Yoon S; Curtis C; Petrov DA; Winslow MM
Nat Genet; 2018 Apr; 50(4):483-486. PubMed ID: 29610476
[TBL] [Abstract][Full Text] [Related]
18. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
19. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
